Abiraterone pharmacokinetics were similar in chemotherapy-pretreated and - nave patients and were characterized by a high between - and within-subject variability [ e.g. , between-subject coefficient of variation ( CV % ) for relative bioavailability for the modified fasting state was 61.1 % and the CV % for within-subject variability was 71.3 % ] .